JP2021500880A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500880A5
JP2021500880A5 JP2020521360A JP2020521360A JP2021500880A5 JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5 JP 2020521360 A JP2020521360 A JP 2020521360A JP 2020521360 A JP2020521360 A JP 2020521360A JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5
Authority
JP
Japan
Prior art keywords
vector
adenovirus vector
expression cassette
monkey adenovirus
saladenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020521360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/078210 external-priority patent/WO2019076880A1/en
Publication of JP2021500880A publication Critical patent/JP2021500880A/ja
Publication of JP2021500880A5 publication Critical patent/JP2021500880A5/ja
Ceased legal-status Critical Current

Links

JP2020521360A 2017-10-16 2018-10-16 2つの発現カセットを有するサルアデノウイルスベクター Ceased JP2021500880A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572944P 2017-10-16 2017-10-16
US62/572,944 2017-10-16
PCT/EP2018/078210 WO2019076880A1 (en) 2017-10-16 2018-10-16 SIMIENS ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES

Publications (2)

Publication Number Publication Date
JP2021500880A JP2021500880A (ja) 2021-01-14
JP2021500880A5 true JP2021500880A5 (enExample) 2021-11-25

Family

ID=63896161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020521360A Ceased JP2021500880A (ja) 2017-10-16 2018-10-16 2つの発現カセットを有するサルアデノウイルスベクター

Country Status (10)

Country Link
US (2) US20200299651A1 (enExample)
EP (1) EP3697918B1 (enExample)
JP (1) JP2021500880A (enExample)
CN (1) CN111479926A (enExample)
AR (1) AR114989A1 (enExample)
BR (1) BR112020007413A2 (enExample)
CA (1) CA3084346A1 (enExample)
ES (1) ES3056141T3 (enExample)
MX (1) MX2020003746A (enExample)
WO (1) WO2019076880A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
CN115427073A (zh) * 2020-01-28 2022-12-02 科达金尼克斯有限公司 去优化SARS-CoV-2及其方法和用途
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CN1965086B (zh) * 2004-04-28 2012-12-26 宾夕法尼亚大学托管会 多价病毒载体和产生它的系统
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
EP3059875B1 (en) 2008-09-27 2019-01-30 WiTricity Corporation Wireless energy transfer systems
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
WO2013052859A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
EP3154576A1 (en) * 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016198621A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection

Similar Documents

Publication Publication Date Title
Chang Adenovirus vectors: excellent tools for vaccine development
JP2017514483A5 (enExample)
Tatsis et al. Adenoviruses as vaccine vectors
CN103998604B (zh) Hbv聚合酶突变体
RU2016146664A (ru) Аденовирус, содержащий альбумин-связывающий участок
JP2014516536A5 (enExample)
JP2014512171A5 (enExample)
JP2016538885A5 (enExample)
JP2019523648A5 (enExample)
JP2015506179A5 (enExample)
JP2018537984A5 (enExample)
JP2014503206A5 (enExample)
JP2018520997A5 (enExample)
JP2019526580A5 (enExample)
JP2016539946A5 (enExample)
CA2863964A1 (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
JP2023517934A5 (enExample)
JP2016513115A5 (enExample)
JP2019520841A5 (enExample)
CN113226364A (zh) 组合物和方法
JP2020537525A5 (enExample)
JP2020537526A5 (enExample)
Bisgin et al. Current update on severe acute respiratory syndrome coronavirus 2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination
JP2020527167A5 (enExample)
JP2018526994A5 (enExample)